Diisopropyl ketone hydrazone | 62104-18-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Diisopropyl ketone hydrazone
• 英文别名: (2,4-Dimethylpentan-3-ylidene)hydrazine；2,4-dimethylpentan-3-ylidenehydrazine
• CAS: 62104-18-1
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: KPLLJVCJQQBIRP-UHFFFAOYSA-N

物化性质

• 沸点：
  65-66 °C(Press: 6.5 Torr)
• 密度：
  0.89±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  38.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Diisopropyl ketone hydrazone 在 碘 、 三乙胺 作用下， 以18%的产率得到2,4-dimethyl-3-iodo-2-pentene
  参考文献：
  名称：

  Competition of Mechanisms in Nucleophilic Substitution of Vinyl Halides. An Unequivocal Example of the Vinylic SRN1 Route1

  摘要：

  In a search for an unambiguous example of the vinylic S(RN)1 route, several vinyl bromides and iodides were reacted mostly with (-)CH(2)COCMe(3), and sometimes with (-)CH(2)COPh, (CH)-C--(Me)COEt, and (EtO)(2)PO- ions, under Fe2+- or photostimulation in Me(2)SO. Vinyl halides having vinylic hydrogens, such as beta-bromostyrene, gave acetylenic products, e.g., phenylacetylene or a tertiary PhC=C-substituted alcohol, whereas vinyl halides with allylic hydrogens, such as Me(2)C=C(I)CHMe(2), gave a substituted allene. Reduction products of the halogen, as well as substitution and rearranged substitution products, were also formed. The operation of ionic elimination-addition routes accounts for formation of most of the products, while the reduction products arise from an intermediate vinyl radical. Ph(2)C=C(Br)Ph (20) and Me(2)C=C(Br)Ph (25) gave both substitution and reduction products, but Me(2)C=C(Br)-t-Bu (23) gave only a reduction product. Formation of substitution products from the conjugated 20 and 25 was ascribed to a reaction via a vinylic S(RN)1 route, while lack of substitution in 23 is related to its nonconjugated system and to the consequent higher energy that the radical anion of the substitution product would have. The one here reported seems to be the first case of an exclusive genuine vinylic S(RN)1 process.

  DOI：

  10.1021/jo00101a045
• 作为产物：
  描述：

  2,4-二甲基-3-戊酮 在 hydrazine hydrate 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 16.0h， 生成 Diisopropyl ketone hydrazone
  参考文献：
  名称：

  N-异氰酸酯和N-异硫氰酸酯的环加成反应合成环甲亚胺亚胺

  摘要：

  各种氮取代的异（硫）氰酸酯参与[3 + 2]-环加成反应，形成包含三唑酮，三唑-硫酮和吡唑-硫酮核的甲亚胺亚胺。首先，显示亚氨基异硫氰酸酯与张力烯烃发生氨基硫代羰基化反应，并且与最近报道的亚氨基异氰酸酯反应进行比较表明其反应性降低。相比之下，亚胺与亚氨基异氰酸酯和亚氨基异硫氰酸酯的氨基（硫）羰基化反应被证明更有效，提供了进入三唑酮和三唑硫酮核的途径。偶极子产物可以通过简单的衍生化反应转化为有价值的杂环核。

  DOI：

  10.1021/acs.orglett.6b01788

文献信息

• [EN] QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE<br/>[FR] INHIBITEURS DE LA QUINOLÉINE DE RAD52 ET MÉTHODES D'UTILISATION
  申请人：UNIV DREXEL

  公开号：WO2021067604A1

  公开（公告）日：2021-04-08

  The present disclosure related to compounds of Formula I and Formula I and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating RAD51 activity and may be used in the treatment of disorders in which RAD51 activity is implication, such as a cancer.

  本公开涉及到Formula I和Formula I的化合物及其药用盐、药物组合物、使用方法和制备方法。本文披露的化合物可用于调节RAD51活性，并可用于治疗RAD51活性参与的疾病，如癌症。
• 1,5-Diaryl-Pyrazoles As Cannabinoid Receptor Neutral Antagonists Useful As Therapeutic Agents
  申请人：Greig Iain Robert

  公开号：US20100022611A1

  公开（公告）日：2010-01-28

  The present invention pertains to cannabinoid (CB) receptor neutral antagonists, and especially CB1 neutral antagonists, and including, for example, certain 1,5 -di-aryl-pyrazole compounds. The present invention also pertains to the use of such compounds in the treatment of diseases and disorders that are ameliorated by treatment with a neutral antagonist of the cannabinoid type 1 (CB1) receptor, for example: an eating disorder; obesity; a disease or disorder characterised by an addiction component; addiction; withdrawal; smoking addiction; smoking withdrawal; drug addiction; drug withdrawal; smoking cessation therapy; a bone disease or disorder; osteoporosis, Paget's disease of bone; bone related cancer; a disease or disorder with an inflammatory or autoimmune component; rheumatoid arthritis; inflammatory bowel disease; psoriasis; a psychiatric disease or disorder; anxiety; mania; schizophrenia; a disease or disorder characterised by impairment of memory and/or loss of cognitive function; memory impairment; loss of cognitive function; Parkinson's disease; Alzheimer's disease; dementia; a cardiovascular disease or disorder; congestive heart failure; cardiac hypertrophy; and myocardial infarction.

  本发明涉及大麻素（CB）受体中和拮抗剂，特别是CB1中和拮抗剂，包括例如某些1,5-二芳基吡唑化合物。本发明还涉及使用这些化合物治疗通过与大麻素类型1（CB1）受体的中和拮抗剂治疗改善的疾病和疾病，例如：进食障碍；肥胖症；以成瘾成分为特征的疾病或疾病；成瘾；戒断；吸烟成瘾；戒烟；药物成瘾；药物戒断；戒烟疗法；骨疾病或疾病；骨质疏松症，骨的帕吉特病；与骨有关的癌症；具有炎症或自身免疫成分的疾病或疾病；类风湿性关节炎；炎症性肠病；牛皮癣；精神疾病或疾病；焦虑症；狂躁症；精神分裂症；以记忆受损和/或认知功能丧失为特征的疾病或疾病；记忆障碍；认知功能丧失；帕金森病；阿尔茨海默病；痴呆；心血管疾病或疾病；充血性心力衰竭；心脏肥大；心肌梗塞。
• Synthesis and properties of 3-oxo-1,2-diazetidinium ylides
  作者：Edward C. Taylor、Neil F. Haley、Robert J. Clemens

  DOI：10.1021/ja00416a009

  日期：1981.12
• Giese, Bernd; Erfort, Ulrich, Chemische Berichte, 1983, vol. 116, # 3, p. 1240 - 1251
  作者：Giese, Bernd、Erfort, Ulrich

  DOI：——

  日期：——
• Giese, Bernd; Erfort, Ulrich, Angewandte Chemie, 1982, vol. 94, # 2, p. 133
  作者：Giese, Bernd、Erfort, Ulrich

  DOI：——

  日期：——